Last updated: March 13, 2026
What is the Drug with NDC 72241-0031?
NDC 72241-0031 corresponds to Edosporin (generic: voriconazole), an antifungal agent approved for invasive fungal infections, including aspergillosis and candidiasis. It is marketed by a Biopharmaceutical company specializing in antifungal medications.
Market Overview
Therapeutic Market Size
The antifungal market reached an estimated value of USD 13 billion in 2022, with growth driven by increasing cases of invasive fungal infections, particularly among immunocompromised populations.
Key Competitors
- Voriconazole (generic and branded products)
- Isavuconazole (Cresemba)
- Posaconazole (Noxafil)
Market share of voriconazole remains dominant due to established efficacy and familiarity.
Pricing Environment
Historically, branded voriconazole has commanded a premium. The introduction of generic formulations has driven prices downward, though branded versions maintain higher prices due to patent protections and brand recognition.
Patent and Regulatory Status
NDC 72241-0031 is associated with a branded formulation. The patent protection for voriconazole expired in the U.S. in 2022 (likely at the end of patent term extensions), paving the way for generic entry.
Patent Timeline
- Original patent expiry: 2022
- Generic approval timeline: Expected by late 2022 or early 2023
- Market entry impact: Potential significant price erosion with generics available shortly
Price Projections
Current Price Benchmarks
- Branded voriconazole (Vfend): USD 150-200 per vial
- Generic voriconazole: USD 80-120 per vial
Short-Term (Next 12 Months)
- Expect continued price stability for brand due to supply constraints and manufacturing pipelines.
- For generics, prices are projected to settle around USD 75-100 per vial, a 30-50% reduction from branded prices.
Medium to Long-Term (1-3 Years)
- Increased generic market penetration may reduce average drug prices further, potentially to USD 50-80 per vial.
- Price competition could drive many manufacturers to lower prices to gain market share.
- Price stabilization is likely once market players settle on a competitive equilibrium.
Market Dynamics Impacting Prices
- Manufacturing capacities: Entry of multiple generics could oversupply the market, pushing prices lower.
- Reimbursement policies: Payers may prefer generics, reducing patient out-of-pocket expenses and incentivizing formulary switches.
- Supply chain considerations: Potential shortages or supply disruptions could impact available pricing.
Revenue Projections
Assumed Volume Estimates
- Year 1 (2023): 2 million vials sold; 70% branded, 30% generic
- Year 2 (2024): 2.5 million vials; increased generic share to 50%
- Year 3 (2025): 3 million vials; majority generic
Revenue Estimate (USD millions)
| Year |
Branded sales (USD millions) |
Generic sales (USD millions) |
Total Revenue |
| 2023 |
210 (USD 150 x 1.4M) |
135 (USD 90 x 1.5M) |
345 |
| 2024 |
250 (USD 150 x 1.67M) |
225 (USD 90 x 2.5M) |
475 |
| 2025 |
200 (USD 125 x 1.6M) |
240 (USD 80 x 3M) |
440 |
Note: These projections assume market entry with full generic competition by 2023, with prices adjusting downward as competition intensifies.
Key Structural Factors
- Patent expiry and timing of generic approval
- Regulatory approvals in key markets (US, Europe, Asia)
- Reimbursement and formulary inclusion strategies
- Clinical guidelines evolution and resistance patterns
Final Considerations
The launch of multiple generics following patent expiration will significantly erode branded product sales and prices. Industry players should monitor regulatory timelines and market acceptance to refine revenue forecasts.
Key Takeaways
- Market for voriconazole (NDC 72241-0031) faces imminent price decline upon patent expiry.
- Branded products currently priced at USD 150-200 per vial; generics expected to settle at USD 50-80.
- Total revenue for the drug may decrease by 20-30% as generics capture significant market share.
- Competitive pressures will likely sustain low prices over 2-3 years.
- Supply chain and reimbursement policies will influence pricing stability.
FAQs
1. When will generic versions of NDC 72241-0031 become widely available?
Generic approvals are expected late 2022 or early 2023, following patent expiration.
2. How will prices change post-generic entry?
Prices are projected to fall approximately 30-50%, stabilizing over 1-3 years.
3. What factors could delay generic entry or price decline?
Regulatory hurdles, supply chain issues, or legal challenges could slow generic approval and market penetration.
4. Which markets have the highest potential for voriconazole sales?
The U.S., Europe, and Japan remain primary markets, aligning with high incidence rates of invasive fungal infections.
5. How might changing clinical guidelines affect demand?
Increased resistance or new treatment protocols could reduce future off-label or expanded use, impacting overall sales.
References
- IQVIA. (2022). Global Pharmaceutical Market Reports.
- FDA. (2022). Patents and Exclusivity Data for Voriconazole.
- MarketWatch. (2023). Antifungal Drugs Market Size and Trends.
- Statista. (2023). Pharmaceutical Pricing Trends.
- FDA. (2023). Generic Drug Approvals.
